Castle Biosciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Diagnostics & Research
CASTELLE
Current Price
$19.13
+1.32%GoodMoat Value
$28.46
48.8% undervaluedProfile
Valuation (TTM)
Market Cap$568.76M
P/E-44.32
EV—
P/B1.21
Shares Out29.73M
P/Sales1.67
Revenue$339.92M
EV/EBITDA—
Castle Biosciences Inc (CSTL) Stock Analysis
Market Cap$568.76M
Current Price$19.13
P/E Ratio-44.32
Forward P/E—
PEG Ratio0.97
EPS$-0.83
Book Value$15.84
P/B Ratio1.21
CSTL Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 29.3% FCF growth (CAGR)
Cash vs Debt
Net Cash: 80M
Revenue
52M
FY19
63M
FY20
94M
FY21
137M
FY22
220M
FY23
332M
FY24
344M
FY25
Net Income
5M
FY19
—
FY20
—
FY21
—
FY22
—
FY23
18M
FY24
—
FY25
CSTL 52-Week Range
$14.65
$43.04
50-Day MA: $24.12200-Day MA: $28.64
Did you know?
Price sits at 16% of its 52-week range.
Castle Biosciences Inc (CSTL) Financial Summary
Castle Biosciences Inc (CSTL) is a Healthcare company in the Diagnostics & Research industry, listed on NASDAQ. The stock currently trades at $19.13 with a market capitalization of $568.76M.
Key valuation metrics include a P/E ratio of -44.32, price-to-book ratio of 1.21, and EPS of $-0.83. The company reports a profit margin of -3.8% and return on equity of -2.7%.
CSTL Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $568.76M |
| P/E Ratio | -44.32 |
| EPS | $-0.83 |
| P/B Ratio | 1.21 |
| P/S Ratio | 1.67 |
| Profit Margin | -3.8% |
| Return on Equity | -2.7% |
| Debt/Equity | 0.08 |
CSTL Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $51.87M | $5.28M |
| FY20 | $62.65M | $-10.28M |
| FY21 | $94.08M | $-31.29M |
| FY22 | $137.04M | $-67.14M |
| FY23 | $219.79M | $-57.47M |
| FY24 | $332.07M | $18.25M |
| FY25 | $344.23M | $-24.16M |
Castle Biosciences Inc (CSTL) Valuation
Based on GoodMoat's DCF model, Castle Biosciences Inc has a fair value estimate of $28.46. At the current price of $19.13, the stock appears 32.8% undervalued relative to our intrinsic value estimate.
CSTL Quality Indicators
Castle Biosciences Inc maintains a profit margin of -3.8% and an operating margin of -12.4%. Return on equity stands at -2.7%. The current ratio is 5.26. Debt-to-equity ratio is 0.08.
About Castle Biosciences Inc
CASTELLE
CSTL Free Cash Flow
Castle Biosciences Inc generated $28.37M in trailing twelve-month free cash flow, representing an FCF yield of 4.99%. This moderate FCF yield indicates reasonable cash generation.
CSTL Shares Outstanding
Castle Biosciences Inc has 0.03 billion shares outstanding at a share price of $19.13, giving it a market capitalization of $568.76M.